In the last decade, major changes have occurred in diagnostic criteria, staging system, and response criteria for multiple myeloma (MM).1, 2 These been accompanied by several advances treatment of MM, including many new drugs (carfilzomib, pomalidomide, daratumumab, elotuzumab, panobinostat, ixazomib, selinexor, isatuximab, belantamab). Numerous clinical trials provide data on best practices al...

Background Carfilzomib is a second-generation irreversible proteasome inhibitor that efficacious in the treatment of myeloma and carries less risk peripheral neuropathy than first-generation inhibitors, making it more amenable to combination therapy. Methods findings The Myeloma XI+ trial recruited patients from 88 sites across UK between 5 December 2013 20 April 2016. Patients with newly diagn...